ENTX

Entera Bio Ltd. · NASDAQ

Performance

-4.55%

1W

+28.83%

1M

+3.45%

3M

-0.47%

6M

+250.0%

YTD

+195.77%

1Y

Profile

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Technical Analysis of ENTX 2024-12-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 76 indicating positive momentum, while the Oscillators Score of 46 suggests a neutral stance, and the Technical Score of 61 reinforces the bullish outlook. This combination implies a generally favorable market condition, though caution may be warranted due to t...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ENTX

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.